The development of molecularly targeted treatments of adult leukemias warrants investigation of these targets in similar pediatric leukemias. The NF1 tumor suppressor gene, which encodes a GTPase activating protein for p21ras, is frequently inactivated in juvenile myelomonocytic leukemia (JMML). Other patients with JMML acquire activating RAS gene mutations. Recipient mice reconstituted with Nf1-/- fetal hematopoietic cells develop a myeloproliferative disease (MPD) that models the human disease. JMML arises from clonal expansion of a hematopoietic stem cell, and JMML cells and murine Nf1-/- hematopoietic cells are hypersensitive to granulocyte macrophage-colony stimulating factor and KitL, the ligand for c-kit. We generated embryos doubly mutant for the Wv allele of c-kit and Nf1 to ask if reduction of c-kit activity would delay or prevent the development of MPD. Despite a reduction in c-kit activity to approximately 10% of wild-type levels, Nf1-/-; Wv/Wv cells induced MPD in recipient mice. © 2003 by The American Society of Hematology.
CITATION STYLE
Ingram, D. A., Wenning, M. J., Shannon, K., & Clapp, D. W. (2003). Leukemic potential of doubly mutant Nf1 and Wv hematopoietic cells. Blood, 101(5), 1984–1986. https://doi.org/10.1182/blood-2002-08-2635
Mendeley helps you to discover research relevant for your work.